Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (117939)	8/8/2003 10:29:31 AM
From: Rocket Red	Respond to of 150070

Lifeline Updates Nipplescope Breast Cancer Detection System RENO, Nev.--(BUSINESS WIRE)--Aug. 8, 2003--Jim Holmes, CEO of Lifeline BioTechnologies, Inc. (OTC:LBTT) announced today that he and Louis Keith, MD, Ph.D., Lifeline's Medical Director, recently visited the London research site where the Company's duct-microendoscope is undergoing clinical testing. Holmes and Keith held discussions with Dr. K. Mokbel, who has been investigating Lifeline's nipple endoscope since January 2003. Dr. Mokbel stated that women presenting with pathological nipple discharge usually have a mammogram and/or ultrasound scan. Ten percent of these women will have an abnormality on imaging which can be biopsied using image-guided needle biopsy. The remaining women are usually advised to have duct excision. Nipple endoscopy can avoid the need for duct excision surgery in 85% of such patients (assumptions: 90% success rate for nipple endoscopy and 5% of patients will require duct excision anyway after successful nipple endoscopy). Furthermore, nipple endoscopy is more likely to show the cause of pathological nipple discharge than duct excision, as the cause is more than 4 cm away from the nipple in 20% of the cases. This means that nipple endoscopy is more likely to detect cancer. Overall, approximately 2.5% of women undergoing duct excision for pathological nipple discharge will be found to have cancer. Dr. Keith stated that in cases where patients present with a nipple discharge, the physician must establish if the discharge is associated with significant underlying pathology. It must be determined if the discharge is spontaneous or induced; whether it arises from a single duct or multiple ducts, and whether it is from one breast or both breasts. Drs. Mokbel and Keith both agree the being able to visually inspect the ducts of the breast with the added advantage of obtaining cells from ducts for cytological examination before the decision to do subsequent surgery would be a significant step toward improved breast cancer detection. According to Dr. William Reeves, Lifeline's President and founder, nipple discharge accounts for approximately 5% of all referrals to breast cancer clinics in our country and it is a frightening symptom because of a woman's fear of breast cancer. Reeves went on to say, nipple discharge and patient age are certainly important predictors of potential malignancy. In one study, 3% of patients younger than 40, 10% of patients between 40 and 60, and 32% of patients older than 60 who presented with nipple discharge as their only symptom, were found to have cancer. CEO Holmes commented, "With this progress, we are moving from a clinical prototype to a production model and preparing to obtain a CE mark for European marketing of the nipple endoscope later this year." This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "will," "anticipated," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties. The Company takes no obligation to update or correct forward-looking statements. --30--CA/se* CONTACT: Lifeline BioTechnologies, Inc. Jim Holmes, 775-852-3222 jholmes777@aol.com or Investor Relations Contact: STOCK ENTERPRISES, INC. Jim Stock, 702-614-0003 KEYWORD: CALIFORNIA NEVADA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES MEDICAL SOURCE: Lifeline BioTechnologies, Inc. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 2003, Business Wire